Zobrazeno 1 - 4
of 4
pro vyhledávání: ''
Autor:
Florian Scotté, Luigi Celio, Yolanda Escobar, Alessandra Franceschetti, Karin Jordan, Danielle Bell, Matti Aapro, Richard Berman
Publikováno v:
Oncologist
Background Guideline-recommended antiemetic prophylaxis improves nausea and vomiting control in most patients undergoing chemotherapy. Multinational Association of Supportive Care in Cancer/European Society for Medical Oncology (MASCC/ESMO) antiemeti
Autor:
William L. Bailey, Kathryn J. Ruddy, Lee S. Schwartzberg, Rebecca Clark-Snow, Thomas W. LeBlanc, Eric Roeland, Rudolph M. Navari, Luke M. Schmerold, Ryan D. Nipp, Ravi Potluri, Eros Papademetriou, Gary Binder
Publikováno v:
Oncologist
Purpose Chemotherapy-induced nausea and vomiting (CINV) contributes to avoidable acute care, a metric now tracked in Medicare's oncology outcome measure. CINV is preventable, yet guidelines are often not followed. We sought to quantify acute care inv
Autor:
Toshinobu Hayashi, Mototsugu Shimokawa, Keisuke Aiba, Hitoshi Kawazoe, Kazuo Tamura, Toshiaki Saeki, Hirotoshi Iihara
Publikováno v:
The Oncologist
Background We previously reported the results of a prospective study of chemotherapy‐induced nausea and vomiting (CINV) in a cohort of patients who received carboplatin‐based chemotherapy and were selected from a nationwide registry of those sche
Autor:
Anders Ullén, Fredrik Jäderling, Per Grybäck, Mads Agerbæk, Helle Pappot, Jeffrey Yachnin, C.-H. Shah, H. Von Der Maase, Karin Holmsten
Publikováno v:
Shah, C H, Pappot, H, Agerbæk, M, Holmsten, K, Jäderling, F, Yachnin, J, Grybäck, P, von der Maase, H & Ullén, A 2019, ' Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor) : Phase I Trial ', Oncologist, vol. 24, no. 6, pp. 745-e213 . https://doi.org/10.1634/theoncologist.2018-0795
The Oncologist
The Oncologist
Lessons Learned First trial to report safety and activity of the microtubule inhibitor vinflunine plus the tyrosine kinase inhibitor sorafenib in post-platinum metastatic urothelial cancer (mUC) patients. A recommended phase II dose was identified fo